Ivabradine HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317108

CAS#: 148849-67-6 (HCl)

Description: Ivabradine is a novel medication used for the symptomatic management of stable angina pectoris. Ivabradine acts by reducing the heart rate via specific inhibition of the funny channel, a mechanism different from that of beta blockers and calcium channel blockers, two commonly prescribed antianginal drugs. Ivabradine is a cardiotonic agent. Ivabradine was approved in 2015. Ivabradine acts on the If (f is for "funny", so called because it had unusual properties compared with other current systems known at the time of its discovery) ion current, which is highly expressed in the sinoatrial node. If is a mixed Na+–K+ inward current activated by hyperpolarization and modulated by the autonomic nervous system. It is one of the most important ionic currents for regulating pacemaker activity in the sinoatrial (SA) node. Ivabradine selectively inhibits the pacemaker If current in a dose-dependent manner. Blocking this channel reduces cardiac pacemaker activity, slowing the heart rate and allowing more time for blood to flow to the myocardium.

Chemical Structure

Ivabradine HCl
CAS# 148849-67-6 (HCl)

Theoretical Analysis

MedKoo Cat#: 317108
Name: Ivabradine HCl
CAS#: 148849-67-6 (HCl)
Chemical Formula: C27H37ClN2O5
Exact Mass:
Molecular Weight: 505.05
Elemental Analysis: C, 64.21; H, 7.38; Cl, 7.02; N, 5.55; O, 15.84

Price and Availability

Size Price Availability Quantity
50.0mg USD 190.0 Same day
100.0mg USD 350.0 Same day
200.0mg USD 650.0 Same day
500.0mg USD 1250.0 Same day
1.0g USD 1550.0 Same day
2.0g USD 2250.0 Same day
5.0g USD 2950.0 Same day
10.0g USD 3650.0 Same day
20.0g USD 4250.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Related CAS #: 155974-00-8 (free base)   1202000-62-1 (sulfate)   148849-67-6 (HCl)   1086026-42-7 (oxalate)    

Synonym: S16257; S 16257; S-16257; S 16257-2; S-16257-2; S16257-2; Ivabradine HCl; Corlentor; Procoralan; Coralan; Coraxan; Ivabid; Bradia.

IUPAC/Chemical Name: (S)-3-(3-(((3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-benzo[d]azepin-2-one hydrochloride


InChi Code: InChI=1S/C27H36N2O5.ClH/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30;/h12-14,16,21H,6-11,15,17H2,1-5H3;1H/t21-;/m1./s1


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 505.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548107/ PubMed PMID: 31643437.

2: Zhu H, Xu X, Fang X, Zheng J, Zhao Q, Chen T, Huang J. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials. Clin Ther. 2019 Oct;41(10):2137-2152.e12. doi: 10.1016/j.clinthera.2019.08.008. Epub 2019 Sep 21. Review. PubMed PMID: 31548105.

3: Mayhew A, Loshak H. Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May 15. Available from http://www.ncbi.nlm.nih.gov/books/NBK545894/ PubMed PMID: 31487130.

4: Zhou Y, Wang J, Meng Z, Zhou S, Peng J, Chen S, Wang Q, Sun K. Pharmacology of Ivabradine and the Effect on Chronic Heart Failure. Curr Top Med Chem. 2019;19(21):1878-1901. doi: 10.2174/1568026619666190809093144. Review. PubMed PMID: 31400267.

5: Sattar Y, Neisani Samani E, Zafrullah F, Latchana S, Patel NB. Ivabradine in Congestive Heart Failure: Patient Selection and Perspectives. Cureus. 2019 Apr 13;11(4):e4448. doi: 10.7759/cureus.4448. Review. PubMed PMID: 31205834; PubMed Central PMCID: PMC6561528.

6: Katsi V, Skalis G, Kallistratos MS, Tsioufis K, Makris T, Manolis AJ, Tousoulis D. Ivabradine and metoprolol in fixed dose combination: When, why and how to use it. Pharmacol Res. 2019 Aug;146:104279. doi: 10.1016/j.phrs.2019.104279. Epub 2019 May 17. Review. PubMed PMID: 31108185.

7: Bocchi EA, Salemi VMC. Ivabradine for treatment of heart failure. Expert Opin Drug Saf. 2019 May;18(5):393-402. doi: 10.1080/14740338.2019.1612873. Epub 2019 May 10. Review. PubMed PMID: 31074301.

8: Sathyamurthy I, Newale S. Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications. Indian Heart J. 2018 Dec;70 Suppl 3:S435-S441. doi: 10.1016/j.ihj.2018.08.008. Epub 2018 Aug 20. Review. PubMed PMID: 30595304; PubMed Central PMCID: PMC6309574.

9: CADTH Canadian Drug Expert Committee Recommendation: Ivabradine Hydrochloride (Lancora — Servier Canada Inc.): Indication: Heart Failure, NYHA class II to III [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May 24. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK533855/ PubMed PMID: 30462447.

10: Pharmacoeconomic Review Report: Ivabradine hydrochloride (Lancora) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK533848/ PubMed PMID: 30462445.

11: Patient Group Input Submissions: Ivabradine (Lancora) for Heart failure, NYHA class II to IV [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK533856/ PubMed PMID: 30462443.

12: Clinical Review Report: Ivabradine hydrochloride (Lancora) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK533838/ PubMed PMID: 30462437.

13: Badu-Boateng C, Jennings R, Hammersley D. The therapeutic role of ivabradine in heart failure. Ther Adv Chronic Dis. 2018 Jul 4;9(11):199-207. doi: 10.1177/2040622318784556. eCollection 2018 Nov. Review. PubMed PMID: 30364460; PubMed Central PMCID: PMC6196638.

14: Dodd K, Lampert BC. The Use and Indication of Ivabradine in Heart Failure. Heart Fail Clin. 2018 Oct;14(4):493-500. doi: 10.1016/j.hfc.2018.06.001. Epub 2018 Aug 18. Review. PubMed PMID: 30266358.

15: Reed M, Nicolas D. Ivabradine. 2019 Oct 8. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK507783/ PubMed PMID: 29939560.

16: Chow SL, Page RL 2nd, Depre C. Role of ivabradine and heart rate lowering in chronic heart failure: guideline update. Expert Rev Cardiovasc Ther. 2018 Jul;16(7):515-526. doi: 10.1080/14779072.2018.1489235. Epub 2018 Jul 2. Review. PubMed PMID: 29902387.

17: Kaski JC, Gloekler S, Ferrari R, Fox K, Lévy BI, Komajda M, Vardas P, Camici PG. Role of ivabradine in management of stable angina in patients with different clinical profiles. Open Heart. 2018 Mar 9;5(1):e000725. doi: 10.1136/openhrt-2017-000725. eCollection 2018. Review. PubMed PMID: 29632676; PubMed Central PMCID: PMC5888443.

18: Gee ME, Watkins AK, Brown JN, Young EJA. Ivabradine for the Treatment of Postural Orthostatic Tachycardia Syndrome: A Systematic Review. Am J Cardiovasc Drugs. 2018 Jun;18(3):195-204. doi: 10.1007/s40256-017-0252-1. Review. PubMed PMID: 29330767.

19: Mathew ST, Po SS, Thadani U. Inappropriate sinus tachycardia-symptom and heart rate reduction with ivabradine: A pooled analysis of prospective studies. Heart Rhythm. 2018 Feb;15(2):240-247. doi: 10.1016/j.hrthm.2017.10.004. Epub 2017 Oct 7. Review. PubMed PMID: 29017929.

20: Kang S, Li CJ, Zhang XM. Ivabradine has a neutral effect on mortality in randomized controlled trials. Medicine (Baltimore). 2017 Oct;96(40):e8067. doi: 10.1097/MD.0000000000008067. Review. PubMed PMID: 28984762; PubMed Central PMCID: PMC5737998.

Additional Information

Related CAS#
155974-00-8 (Ivabradine)
1202000-62-1 (Ivabradine sulfate)
148849-67-6 (Ivabradine hydrochloride)